Acute inflammatory and chronic fibrotic lung diseases result in high mortality and morbidity and clinical trials across the world show that MSC therapy holds great promise. During the 2020 COVID-19 pandemic, MSCs emerged as a promising treatment for seriously affected patients with ARDS (Acute Respiratory Distress Syndrome) requiring mechanical ventilation.